Belatacept-based immunosuppression in heart transplant recipients: A single center experience.

JHLT Open · 2025 · PMC12205671 · PMID 40584719

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Recipients on the belatacept-based regimen during follow-up showed a trend of no incidence of de novo DSA compared to the tacrolimus-based immunosuppression controls.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.